Clinical trial NCT03447756: Titration Study of ABX-1431
Official title: A Randomized, Placebo-Controlled, Optimized Titration Study of ABX-1431 in Adult Patients With Peripheral Neuropathic Pain
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Post Herpetic Neuralgia
Diabetic Peripheral Neuropathy
Small Fiber Neuropathy
Post-Traumatic Neuralgia
Lead sponsor: Abide Therapeutics
Sponsor class: INDUSTRY
First posted: 2018-02-27
Enrollment: 39
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is designed to identify a titration regimen of ABX-1431 in adults with neuropathic pain with satisfactory tolerability to central nervous system (CNS) adverse events (AEs). During the course of this study, each participant will take a daily dose of ABX-1431 or a matching placebo for 28 days.

Detailed description: This is a double-blind, placebo-controlled, optimized titration study of ABX-1431 HCl. The study will explore whether patients experiencing ABX-1431-related CNS AE accommodate or become tolerant to them with continued dosing. The efficacy of ABX-1431 in treating neuropathic pain will be assessed by the change from baseline in pain intensity scores using numerical rating scale (NRS-11).

All patients will undergo a screening visit for enrollment criteria. Eligible patients will be treated with daily medication for 28 days which will include some treatment with placebo and some treatment with ABX-1431 HCl. Patients will record their daily average pain using a paper numerical rating scale (NRS-11).

This study will enroll up to 32 patients with peripheral neuropathic pain due to one of the four following diagnostic groups: post-herpetic neuralgia, diabetic peripheral neuropathy, small fiber neuropathy or post-traumatic neuropathic pain.

Eligibility criteria: Key Inclusion Criteria:

* Patient is a male or female over the age of 18 years of age at the Screening Visit.
* Patient has a peripheral neuropathic pain in one of the following diagnostic groups that is persistent for \> 3 months

  * Post-herpetic neuralgia
  * Diabetic peripheral neuropathy
  * Small fiber neuropathy
  * Post-traumatic neuropathic pain
* Patient's median NRS-11 pain intensity score must be ≥ 4 during the baseline period
* If a patient enters the trial on daily background neuropathic pain medications, then the patient must be on stable dose of medications for at least 30 days before enrollment and throughout the study.
* Patient is able to understand and comply with the protocol procedures for the entire trial and must give written informed consent.
* Men and Women must agree to a medically approved contraceptive regimen.

Key Exclusion Criteria:

* Patient is taking potent cytochrome P450 3A4/5 inducers or inhibitors
* Patient has received injection therapies (e.g., botulinum toxin, anesthetic or nerve block) or transcutaneous electrical stimulation to control pain in the past 60 days
* Patient has evidence of alcohol, drug or chemical abuse in the year before the Screening Visit.
* Patient is a lactating or pregnant female or a female who intends to become pregnant within 90 days following the last dose of investigational product.
* Patient has specific laboratory abnormalities

Other protocol-defined inclusion/exclusion criteria may apply.

Primary outcomes:
measure: Identify a titration regimen of ABX-1431
timeFrame: 28 days
Secondary outcomes:
measure: Tolerance to ABX-1431 related CNS AEs determined by whether or not AEs resolve with continued dosing
timeFrame: 28 days
measure: Numerical Rating Scale (NRS-11)
timeFrame: 20 days
Other outcomes:
Locations:
city: Chisinau
country: Moldova, Republic of
facility: Republican Clinical Hospital
Study officials:
affiliation: ARENSIA EXPLORATORY MEDICINE
name: Vitale Lisnic, PhD
role: PRINCIPAL_INVESTIGATOR
References: